Text Size

The Effect of High Dose Salbutamol on Muscle Performance

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT01415596
First received: August 11, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.


Condition Intervention
Ergogenic Effects of Salbutamol in Healthy Males
 Drug: salbutamol
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • Muscle power

Secondary Outcome Measures:
  • Muscle recovery

Enrollment: 20
Study Start Date: August 2011
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Active Comparator: Salbutamol Drug: salbutamol

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males
  • age 18-45
  • training frequency > 10 hrs/wk
  • informed consent

Exclusion Criteria:

  • smoker or former smoker
  • chronic diseases, as well as asthma
  • allergy to the study drugs
  • intake of any form of medicin or inhibited drugs during the study
  • use of beta2-agonist 14 days before the intervention
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01415596

Locations
Denmark
Bispebjerg Hospital
Copenhagen NW, Denmark, DK-2400
Sponsors and Collaborators
Bispebjerg Hospital
University of Copenhagen
  More Information

No publications provided

Responsible Party: Vibeke Backer, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT01415596     History of Changes
Other Study ID Numbers: SALMUS2011
Study First Received: August 11, 2011
Last Updated: August 11, 2011
Health Authority: Denmark: Danish Medicines Agency
Denmark: Good Clinical Practice

Additional relevant MeSH terms:
Albuterol
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
 Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on May 19, 2013